Ignite Creation Date:
2025-12-24 @ 2:44 PM
Ignite Modification Date:
2026-02-25 @ 8:11 PM
Study NCT ID:
NCT00511459
Status:
COMPLETED
Last Update Posted:
2015-10-29
First Post:
2007-08-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-07
Start Date Type:
None
Primary Completion Date:
2010-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-05
Completion Date Type:
ACTUAL
First Submit Date:
2007-08-02
First Submit QC Date:
None
Study First Post Date:
2007-08-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2014-04-23
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2015-10-07
Last Update Post Date:
2015-10-29
Last Update Post Date Type:
ESTIMATED